Hyperkalemia - Epidemiology Forecast - 2032

DelveInsight's 'Hyperkalemia - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Hyperkalemia Disease Understanding

According to National Kidney Foundation, High potassium (called "hyperkalemia") is a medical problem in which a person has excessive potassium in the blood, an important nutrient found in many foods. Potassium helps the nerves and muscles, including the heart, work correctly, but excessive potassium in the blood can be dangerous and cause serious heart problems

While mild hyperkalemia is usually asymptomatic, high potassium levels may cause life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Symptoms usually develop at higher levels, 6.5-7 mEq/L, but the rate of change is more important than the numerical value. Patients with chronic hyperkalemia may be asymptomatic at increased levels, while patients with dramatic, acute potassium shifts may develop severe symptoms at lower ones; infants have higher baseline levels than children and adults.

Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery, or the expression of aldosterone-sensitive ion transporters in the distal nephron.

The major risk factors for hyperkalemia are renal impairment - either AKI or advanced chronic kidney disease (CKD) - and any acquired or inherited defects in potassium excretion in the distal nephron. In CKD, hyperkalemia is typically encountered after the estimated glomerular filtration rate (eGFR) drops below 15 mL/min.

The most notorious consequence of hyperkalemia is potentially fatal cardiac dysrhythmia; however, several other consequences are worthy of discussion. Hyperkalemia is associated with increased mortality. Consequently, hyperkalemia-or the fear of hyperkalemia-may prompt prescribing practice changes (e.g., avoiding RAS blockade and MRAs). Finally, recent data show that hyperkalemia can cause renal tubular acidosis and contribute to peripheral neuropathy in CKD patients.

Hyperkalemia Diagnosis

For hyperkalemia, interviews, physical examinations, blood tests, urinalysis, electrocardiogram tests, etc., are conducted to understand the condition. These tests not only help determine the cause of hyperkalemia but also help determine treatment strategies.

A blood test measures the potassium concentration in the serum; if it is less than 3.5 mEq/L, it is called hypokalemia. In the medical examination, the medical history of symptoms and diseases that are likely to cause it is considered, such as the history of taking drugs, the contents of meals, etc., and perform a blood test to make a comprehensive diagnosis. The cause and severity of hypokalemia are investigated by examining the potassium concentration and excretion in urine, hormone tests such as aldosterone secreted from the adrenal glands, and electrocardiography to check the effects on the heart.

Continued in the report…..

Hyperkalemia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent cases of Hyperkalemia, Gender-specific Diagnosed Prevalent cases of Hyperkalemia, Age-specific Diagnosed Prevalent cases of Hyperkalemia, Severity-specific Diagnosed Prevalent cases of Hyperkalemia, and Comorbidities-specific Diagnosed Prevalent cases of Hyperkalemia scenario of Hyperkalemia in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Hyperkalemia Detailed Epidemiology Segmentation

• In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,046 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019-2032).
• Among the 7MM, the United States accounted for nearly 79% of the total diagnosed prevalent cases of Hyperkalemia in the 7MM in the year 2021 which are expected to increase further by 2032.
• Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.
• In 2021, the diagnosed prevalent population of Hyperkalemia in Japan was found to be approximately 696,891 cases, which is expected to change for the study period of 2019-2032.
• According to estimates based on DelveInsight's epidemiology model for Hyperkalemia, the gender distribution of the disease suggests a male predominance across the 7MM, with approximately 3,016,271 male and 2,500,774 female cases in the 7MM in 2021.
• According to estimates based on DelveInsight's epidemiology model for Hyperkalemia, in the US, the age-specific cases of the disease suggest that the 18-64 years age group make up the majority of the Hyperkalemia cases, followed by 65-79 years age-group. While the least cases were in the = 80 age group.

Scope of the Report:

• The report covers a descriptive overview of Hyperkalemia, explaining its symptoms, comorbidities, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Hyperkalemia.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, Total Diagnosed Prevalent cases of Hyperkalemia, Gender-specific Diagnosed Prevalent cases of Hyperkalemia, Age-specific Diagnosed Prevalent cases of Hyperkalemia, Severity-specific Diagnosed Prevalent cases of Hyperkalemia, and Comorbidities-specific Diagnosed Prevalent cases of Hyperkalemia.

Report Highlights:

• 11-Year Forecast of Hyperkalemia
• The 7MM Coverage
• Total Diagnosed Prevalent Cases of Hyperkalemia
• Gender-specific Diagnosed Prevalent cases of Hyperkalemia
• Age-specific Diagnosed Prevalent cases of Hyperkalemia
• Severity-specific Diagnosed Prevalent cases of Hyperkalemia
• Comorbidities-specific Diagnosed Prevalent cases of Hyperkalemia

Key Questions Answered

• What are the disease risk and burdens of Hyperkalemia?
• What is the historical Hyperkalemia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Hyperkalemia at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with Hyperkalemia?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Hyperkalemia during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Hyperkalemia report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Hyperkalemia epidemiology forecast.
• The Hyperkalemia epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• Hyperkalemia epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study Period: 2019-2032